| Literature DB >> 34588802 |
Junxing Lv1, Qinghao Zhao1, Jingang Yang1, Xiaojin Gao1, Xuan Zhang1, Yunqing Ye1, Qiuting Dong1, Rui Fu1, Hui Sun1, Xinxin Yan1, Wei Li2, Yuejin Yang1, Haiyan Xu1.
Abstract
BACKGROUND: Length of stay (LOS) in patients with ST-segment elevation myocardial infarction (STEMI) is directly associated with financial pressure and medical efficiency. This study aimed to determine impact of LOS on short-term outcomes and associated factors of LOS in patients with ST-segment elevation myocardial infarction (STEMI) after primary percutaneous coronary intervention (PPCI).Entities:
Keywords: ST-segment elevation myocardial infarction; length of stay; primary percutaneous coronary intervention; prognosis
Year: 2021 PMID: 34588802 PMCID: PMC8473847 DOI: 10.2147/IJGM.S330379
Source DB: PubMed Journal: Int J Gen Med ISSN: 1178-7074
Baseline Characteristics for Patients Stratified by LOS
| Variables | LOS≤7d (n=1193) | LOS>7d (n=2422) | P value |
|---|---|---|---|
| Patient demographics | |||
| Age, yrs | 58.52±11.53 | 60.56±11.87 | <0.001 |
| Female | 210 (17.6) | 489 (20.0) | 0.064 |
| Currently single | 27 (2.3) | 93 (3.9) | 0.015 |
| Self-paying medication | 111 (9.8) | 169 (7.2) | 0.008 |
| BMI, kg/m2 | 24.45 (22.57, 26.04) | 24.22 (22.49, 26.12) | 0.217 |
| Medical history | |||
| Diabetes | 221 (19.3) | 425 (18.1) | 0.407 |
| Hypertension | 552 (47.1) | 1147 (48.1) | 0.593 |
| Hyperlipidemia | 71 (6.6) | 157 (7.2) | 0.493 |
| Current smoker | 680 (57.2) | 1209 (50.1) | <0.001 |
| Previous Angina | 229 (19.2) | 456 (18.8) | 0.791 |
| Previous myocardial infarction | 49 (4.1) | 117 (4.8) | 0.329 |
| Previous heart failure | 2 (0.2) | 23 (0.9) | 0.008 |
| Previous stroke | 90 (7.5) | 162 (6.7) | 0.342 |
| Previous PCI | 58 (4.9) | 107 (4.4) | 0.548 |
| Previous CABG | 2 (0.2) | 5 (0.2) | — |
| Previous renal dysfunction | 4 (0.3) | 13 (0.5) | 0.566 |
| Chronic obstructive pulmonary disease | 10 (0.8) | 36 (1.5) | 0.102 |
| Presenting characteristics | |||
| Weekend admission | 306 (25.6) | 696 (28.7) | 0.051 |
| Symptom onset to admission time >12h | 100 (8.4) | 181 (7.5) | 0.340 |
| Heart rate | 75.78±15.41 | 75.14±17.56 | 0.263 |
| Systolic blood pressure, mmHg | 131.70±24.84 | 127.79±25.86 | <0.001 |
| Killip class >I | 158 (13.3) | 452 (18.7) | <0.001 |
| Cardiac arrest | 6 (0.5) | 36 (1.5) | 0.009 |
| LVEF (%) | 55.75±8.50 | 53.54±9.71 | <0.001 |
| Creatinine, μmol/L | 73.00 (62.00, 86.00) | 73.00 (61.00, 87.33) | 0.826 |
| Hemoglobin, g/L | 143.12±17.80 | 140.41±19.32 | <0.001 |
| Leukocyte count, ×109/L | 10.63±3.46 | 10.71±3.44 | 0.508 |
| Na+, mmol/L | 139.37±3.65 | 139.30±4.51 | 0.621 |
| K+, mmol/L | 3.89±0.49 | 3.93±0.50 | 0.019 |
| Procedural and angiographic characteristics | |||
| Transfemoral approach | 193 (16.4) | 282 (12.1) | <0.001 |
| Three-vessel or left main disease | 365 (31.2) | 834 (36.1) | 0.004 |
| Left main or LAD related-infarction | 557 (46.8) | 1239 (51.5) | 0.008 |
| Preprocedural TIMI flow grade 0 | 845 (70.8) | 1786 (73.7) | 0.064 |
| Stent type | <0.001 | ||
| DES | 940 (79.1) | 2079 (86.2) | |
| BMS | 191 (16.1) | 186 (7.7) | |
| Without stent implantation | 57 (4.8) | 148 (6.1) | |
| Postprocedural TIMI flow grade 3 | 1153 (97.3) | 2294 (95.4) | 0.007 |
| Periprocedural complications | 49 (4.1) | 185 (7.6) | <0.001 |
| GP IIb/IIIa inhibitor | 435 (36.7) | 1209 (50.2) | <0.001 |
| IABP insertion | 12 (1.0) | 151 (6.2) | <0.001 |
| In-hospital adverse events | |||
| New-onset heart failure | 33 (2.8) | 256 (10.6) | <0.001 |
| Recurrent myocardial ischemia | 3 (0.3) | 24 (1.0) | 0.026 |
| Recurrent myocardial infarction | 3 (0.3) | 2 (0.1) | 0.419 |
| Stroke | 2 (0.2) | 12 (0.5) | 0.227 |
| Major bleeding | 6 (0.5) | 49 (2.0) | <0.001 |
| Medications at discharge | |||
| Dual antiplatelet therapy | 1173 (99.0) | 2376 (98.4) | 0.151 |
| Statins | 1106 (98.8) | 2241 (98.8) | 0.968 |
| ACE inhibitors/ARB | 758 (64.2) | 1423 (59.5) | 0.007 |
| β-blockers | 848 (71.7) | 1792 (74.7) | 0.051 |
| Hospital characteristics | |||
| Province-level hospitals | 802 (67.2) | 888 (36.7) | <0.001 |
| Number of beds | |||
| ≤100 | 418 (35.0) | 1155 (47.7) | <0.001 |
| 101–300 | 719 (60.3) | 1059 (43.7) | |
| >300 | 56 (4.7) | 208 (8.6) | |
| Hospital region | |||
| North | 796 (66.7) | 1615 (66.7) | 0.980 |
| South | 397 (33.3) | 807 (33.3) | |
| Hospital expenses, Ұ | 76,749.34 (64,407.56, 90,846.00) | 88,438.50 (72,440.30, 107,972.81) | <0.001 |
Note: Data are presented as n (%), mean ± SD or median (quartiles).
Abbreviations: LOS, length of stay; BMI, body mass index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; LAD, left anterior descending; TIMI, Thrombolysis In Myocardial Infarction; DES, drug-eluting stents; BMS, bare-metal stents; GP, glycoprotein; IABP, intra-aortic balloon pump; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker.
Independent Predictors of Prolonged Length of Stay (LOS>7d)
| Variables | Adjusted OR | 95% CI | P value |
|---|---|---|---|
| Patient characteristics | |||
| Age (per 1 year increase) | 1.012 | (1.006, 1.019) | <0.001 |
| BMI (per 1kg/m2 increase) | 0.985 | (0.970, 0.999) | 0.042 |
| Medical history | |||
| Prior heart failure | 5.593 | (1.587, 19.715) | 0.007 |
| Presenting characteristics | |||
| Weekend admission | 1.386 | (1.232, 1.559) | <0.001 |
| Systolic blood pressure (per 1mmHg increase) | 0.996 | (0.994, 0.999) | 0.004 |
| Killip class>I | 1.263 | (1.015, 1.571) | 0.036 |
| Cardiac arrest at admission | 1.782 | (1.017, 3.121) | 0.044 |
| LVEF (per 1% increase) | 0.978 | (0.965, 0.990) | 0.001 |
| Leukocyte count (per 109/L increase) | 1.031 | (1.004, 1.058) | 0.025 |
| Procedural and angiographic characteristics | |||
| Left main or LAD related infarction | 1.187 | (1.039, 1.357) | 0.012 |
| GP IIb/IIIa inhibitor | 1.259 | (1.031, 1.537) | 0.024 |
| IABP insertion | 3.529 | (2.195, 5.675) | <0.001 |
| Hospital characteristics | |||
| Prefecture- and county-level hospitals | 5.979 | (3.308, 10.807) | <0.001 |
| Number of beds | |||
| 101–300 vs ≤100 | 1.262 | (0.721, 2.209) | 0.416 |
| >300 vs ≤100 | 3.609 | (1.127, 11.557) | 0.031 |
Abbreviations: LOS, length of stay; BMI, body mass index; LVEF, left ventricular ejection fraction; LAD, left anterior descending; GP, glycoprotein; IABP, intra-aortic balloon pump; OR, odds ratio; CI, confidence interval.
Figure 130-day clinical outcomes in different LOS groups. (A) MACCE. (B) Readmission. (C) Functional status. MACCE was defined as the composite of cardiac death, cardiovascular readmission, recurrent myocardial infarction, and stroke.
Association Between LOS and 30-Day Outcomes
| Outcomes | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
| Unadjusted OR (95% CI) | P value | Adjusted OR (95% CI) | P value | |
| MACCE | 1.328 (0.913, 1.931) | 0.138 | 1.085 (0.710, 1.657)* | 0.706 |
| All-cause readmission | 1.212 (0.844, 1.740) | 0.298 | 1.060 (0.704, 1.594)* | 0.781 |
| Resting at home | 1.404 (1.215, 1.623) | <0.001 | 1.003 (0.849, 1.185)* | 0.973 |
| Medication adherence | 0.825 (0.706, 0.964) | 0.015 | 0.817 (0.687, 0.971)† | 0.022 |
Notes: *Adjusted for patient demographics, medical history, presenting characteristics, procedural and angiographic characteristics, in-hospital adverse events, medications at discharge, and hospital characteristics; †Adjusted for patient demographics, medical history, presenting characteristics, procedural and angiographic characteristics, in-hospital adverse events, and hospital characteristics.
Abbreviations: LOS, length of stay; MACCE, major adverse cardiac and cerebrovascular events; OR, odds ratio; CI, confidence interval.
Figure 2Comparison of medication usage between at and after discharge in different LOS groups. (A) Dual antiplatelet therapy. (B) Statins. (C) ACE inhibitors/ARB. (D) β-blockers.